Industry Program

Title coming soon. Objectives: Information coming soon. Agenda – Friday 30 October Chairperson: TBC

Latest Evidence on Methotrexate and JAK Inhibitors Objectives: This session will discuss the combination therapy of JAK inhibitors with MTX and JAK inhibitors monotherapy. Agenda – Saturday 31 October Chairperson: Dr Seong-Ho Kim 1730-1825 Latest Evidence on Methotrexate and JAK Inhibitors Prof Yuko Kaneko

Polymyalgia Rheumatica: From Diagnosis to Long-Term Disease Control – Current Recommendations and Unmet Needs Objectives: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease affecting adults aged 50 years and older, characterized by bilateral pain and stiffness in the shoulder and pelvic girdles and a substantial impact on physical function and quality of life. Despite its relatively high prevalence, PMR remains a challenging condition due to heterogeneous clinical presentation, frequent diagnostic uncertainty, and a chronic or relapsing disease course in

UP Standard Of Care in AS with Upadacitiniby Sponsored by Abbvie ObjectivesInformation coming soon. Agenda – Friday 30 October Chairperson: Dr Taehwan Kim TBC Presentation title TBC Prof Xenofon Baraliakos

Title coming soon. Information coming soon.

Reframing Long-Term SLE Care in Asia: Reducing Steroid Burden and Advancing Organ Protection Objectives:This scientific symposium will address contemporary management challenges in SLE in Asia, with emphasis on minimizing cumulative glucocorticoid exposure and preventing organ damage. Faculty will review disease burden and the clinical consequences of prolonged glucocorticoid use, then examine mechanism‑based treatment strategies with a focus on B‑cell biology and evidence supporting BLyS inhibition and other B‑cell–directed approaches. A dedicated segment will discuss lupus nephritis, outlining the rationale and

Informing coming soon. 

Redefining the Autoimmune ILD Journey: From Early Risk Recognition to Long Term Care Objectives:Autoimmune diseases are a major cause of interstitial lung disease (ILD), with pulmonary fibrosis driving morbidity and mortality. This session will examine risk identification, key clinical and radiological signals of progression, and translation of guidelines into personalised care, concluding with emerging concepts and innovations shaping the future management of autoimmune ILD. Agenda – Saturday 31 October Chairperson: Prof Shin-Seok Lee 1250-1300 Opening and welcome remarks Prof Shin-Seok

Title TBC Information coming soon Agenda – Saturday 31 October Chairperson: Seung-Ki Kwok TBC Presentation title TBC Kunihiro Yamaoka

Transforming the Trajectory: Early Inflammation Control as a Path to Lasting Change in Spondyloarthritis Agenda – Saturday 31 October Chairperson: Kichul Shin TBC Presentation title TBC Masato Okada TBC Presentation title TBC Paul Bird